NCT04210869 is a NA clinical trial of Mixed Nuts in Brain Vascular Function, sponsored by Maastricht University Medical Center.

Who is sponsoring NCT04210869?

NCT04210869 is sponsored by Maastricht University Medical Center.

What drugs are being tested in NCT04210869?

Interventions in NCT04210869: Mixed Nuts.

What condition does NCT04210869 study?

NCT04210869 studies Brain Vascular Function, Cerebral Blood Flow.

Is NCT04210869 still recruiting?

NCT04210869 is currently completed. Last updated 14 January 2022.

Last reviewed 2022-01-14 · How we verify

NCT04210869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mixed Nuts and Brain Vascular Function

Completed NA Last updated 14 January 2022

What this trial tests

NA trial testing Mixed Nuts in Brain Vascular Function in 28 participants. Completed in 31 December 2021.

Timeline

1 January 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Maastricht University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	prevention
Enrollment	28
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Netherlands

Drugs / interventions tested

Mixed Nuts

Conditions studied

Brain Vascular Function — all drugs for Brain Vascular Function →
Cerebral Blood Flow — all drugs for Cerebral Blood Flow →

Sponsor

Maastricht University Medical Center

Who can join

Adults 60 to 70, any sex, with Brain Vascular Function or Cerebral Blood Flow. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Impaired brain vascular function precedes the development of reduced cognitive performance, while brain insulin-resistance is also associated with cognitive decline. The Mediterranean diet, which is rich in nuts, may protect against the development of impaired cognitive performance. The hypothesis is that long-term mixed nut consumption increases brain insulin-sensitivity thereby improving brain vascular function and cognitive performance. The primary objective is to evaluate in elderly men and women the effect of 16-week mixed nut consumption on cerebral blood flow, as quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labelling (ASL). Cerebral blood flow is a robust and sensitive physiological marker of brain vascular function. Secondary objectives are to investigate effects on the cerebral blood flow response to intranasal insulin delivery - a marker of insulin-sensitivity in the human brain - as quantified by ASL, and cognitive functioning as assessed with a neuropsychological test battery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mixed nut consumption improves brain insulin sensitivity: a randomized, single-blinded, controlled, crossover trial in older adults with overweight or obesity.
Nijssen KM, Mensink RP, Plat J, Ivanov D, et al · · 2024 · cited 10× · PMID 38128733 · DOI 10.1016/j.ajcnut.2023.12.010
Effects of Longer-Term Mixed Nut Consumption on Lipoprotein Particle Concentrations in Older Adults with Overweight or Obesity.
Nijssen KMR, Chavez-Alfaro MA, Joris PJ, Plat J, et al · · 2024 · cited 2× · PMID 39796442 · DOI 10.3390/nu17010008

Verify or expand the search:

Other recruiting trials for Brain Vascular Function

Currently open trials in the same condition.

NCT07057245 — Effects of Protein Supplementation on Brain Function · NA · recruiting

Other Maastricht University Medical Center trials

Trials by the same sponsor.

NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04210869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
Last refreshed: 14 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04210869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing